Journal
NATURE IMMUNOLOGY
Volume 11, Issue 4, Pages 289-293Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ni.1852
Keywords
-
Categories
Funding
- National Institutes of Health [AI068731, AI044259, AR055695, AR56113, AI061570, AI074878, AI083480]
- Burroughs Wellcome Fund
- Crohn's and Colitis Foundation of America
- University of Pennsylvania
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061570, R21AI083480, R01AI074878, R01AI068731, R01AI044259] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR055695, R01AR056113] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Thymic stromal lymphopoietin (TSLP) is an interleukin 7 (IL-7)-like cytokine originally characterized by its ability to promote the activation of B cells and dendritic cells (DCs). Subsequent studies have shown that TSLP promotes T helper type 2 (T(H)2) cell responses associated with immunity to some helminth parasites and the pathogenesis of many inflammatory diseases, including atopic dermatitis and asthma. This review will focus on recent findings indicating that in addition to influencing B cell and DC function, TSLP can promote T(H)2 cytokine-associated inflammation by directly promoting the effector functions of CD4(+) T(H)2 cells, basophils and other granulocyte populations while simultaneously limiting the expression of DC-derived proinflammatory cytokines and promoting regulatory T cell responses in peripheral tissues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available